<DOC>
	<DOCNO>NCT01516983</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Icotinib different dose level combination whole brain radiotherapy NSCLC patient brain metastasis EGFR mutation .</brief_summary>
	<brief_title>Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases EGFR Mutation</brief_title>
	<detailed_description>The long-term control brain metastasis becomes clinical challenge . Whole brain radiotherapy , standard treatment patient multiple brain metastasis , bring modest survival improvement around 3-6 month . EGFR-TKIs like icotinib proven activity non-small cell lung cancer may provide clinical benefit patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histological cytological confirmation nonsmall cell lung cancer ( NSCLC ) . Diagnosis brain metastasis Gadoliniumenhanced MRI . More 3 site intracranial metastasis , long diameter intracranial lesion 3cm . Positive EGFR mutation . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . CSF MRI finding consistent metastasis spinal cord , meninges meningeal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Icotinib</keyword>
	<keyword>WBRT</keyword>
</DOC>